Lexicon Genetics of The Woodlands, Texas, has altered over one-third of all genes in the mouse genome, which could provide useful information about the human genome for drug discovery.
The company is collecting knockout mouse clones, which are being used by Lexicon and its partners to identify which genes are valuable for drug discovery to treat human disease, said Arthur Sands, Lexicon’s president and CEO.